SKYSCRAPER-02: Tiragolumab in Combination With Atezolizumab Plus Chemotherapy in Untreated Extensive-Stage Small-Cell Lung Cancer
- PMID: 37976444
- PMCID: PMC10824371
- DOI: 10.1200/JCO.23.01363
SKYSCRAPER-02: Tiragolumab in Combination With Atezolizumab Plus Chemotherapy in Untreated Extensive-Stage Small-Cell Lung Cancer
Abstract
Purpose: The phase III SKYSCRAPER-02 study determined whether the benefits of atezolizumab plus carboplatin and etoposide (CE) could be enhanced by the addition of tiragolumab in untreated extensive-stage small-cell lung cancer (ES-SCLC). We report final progression-free survival (PFS) and overall survival (OS) analyses.
Methods: Patients received tiragolumab 600 mg/placebo, plus atezolizumab 1,200 mg and CE (four cycles), then maintenance tiragolumab/placebo plus atezolizumab. Primary end points were investigator-assessed PFS and OS in patients without history/presence of brain metastases (primary analysis set [PAS]). Additional end points included PFS and OS in all patients regardless of brain metastases status (full analysis set [FAS]), response, and safety.
Results: Four hundred ninety patients were randomly assigned (FAS): 243 to tiragolumab arm and 247 to control arm. At the cutoff date (February 6, 2022; median duration of follow-up, 14.3 months [PAS] and 13.9 months [FAS]), final analysis of PFS in the PAS (n = 397) did not reach statistical significance (stratified hazard ratio [HR], 1.11; P = .3504; median, 5.4 months tiragolumab v 5.6 months control). At the cutoff date (September 6, 2022; median duration of follow-up, 21.2 months [FAS]), median OS in the PAS at final OS analysis was 13.1 months in both arms (stratified HR, 1.14; P = .2859). Median PFS and OS in the FAS were consistent with the PAS. The proportion of patients with immune-mediated adverse events (AEs) in the tiragolumab and control arms was 54.4% and 49.2%, respectively (grade 3/4: 7.9% and 7.7%). AEs leading to treatment withdrawal occurred in 8.4% and 9.3% of tiragolumab- and control-treated patients, respectively.
Conclusion: Tiragolumab did not provide additional benefit over atezolizumab and CE in untreated ES-SCLC. The combination was well tolerated with no new safety signals.
Trial registration: ClinicalTrials.gov NCT04256421.
Conflict of interest statement
The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (
Figures




Similar articles
-
Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133).J Clin Oncol. 2021 Feb 20;39(6):619-630. doi: 10.1200/JCO.20.01055. Epub 2021 Jan 13. J Clin Oncol. 2021. PMID: 33439693 Free PMC article. Clinical Trial.
-
Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE): primary and follow-up analyses of a randomised, double-blind, phase 2 study.Lancet Oncol. 2022 Jun;23(6):781-792. doi: 10.1016/S1470-2045(22)00226-1. Epub 2022 May 13. Lancet Oncol. 2022. PMID: 35576957 Clinical Trial.
-
Brief Report: Exploratory Analysis of Maintenance Therapy in Patients With Extensive-Stage SCLC Treated First Line With Atezolizumab Plus Carboplatin and Etoposide.J Thorac Oncol. 2022 Sep;17(9):1122-1129. doi: 10.1016/j.jtho.2022.05.016. Epub 2022 Jun 25. J Thorac Oncol. 2022. PMID: 35764236 Clinical Trial.
-
Atezolizumab: A Review in Extensive-Stage SCLC.Drugs. 2020 Oct;80(15):1587-1594. doi: 10.1007/s40265-020-01398-6. Drugs. 2020. PMID: 32990939 Review.
-
Comparison of First-Line Treatments for Patients With Extensive-Stage Small Cell Lung Cancer: A Systematic Review and Network Meta-analysis.JAMA Netw Open. 2020 Oct 1;3(10):e2015748. doi: 10.1001/jamanetworkopen.2020.15748. JAMA Netw Open. 2020. PMID: 33074323 Free PMC article.
Cited by
-
Metabolism of cancer cells and immune cells in the initiation, progression, and metastasis of cancer.Theranostics. 2025 Jan 1;15(1):155-188. doi: 10.7150/thno.103376. eCollection 2025. Theranostics. 2025. PMID: 39744225 Free PMC article. Review.
-
Turning Cancer Immunotherapy to the Emerging Immune Checkpoint TIGIT: Will This Break Through the Limitations of the Legacy Approach?Vaccines (Basel). 2024 Nov 22;12(12):1306. doi: 10.3390/vaccines12121306. Vaccines (Basel). 2024. PMID: 39771968 Free PMC article.
-
RANO 2.0: critical updates and practical considerations for radiological assessment in neuro-oncology.Jpn J Radiol. 2025 Jun 30. doi: 10.1007/s11604-025-01821-6. Online ahead of print. Jpn J Radiol. 2025. PMID: 40586994 Review.
-
Coordinated translational control of multiple immune checkpoints by the integrated stress response pathway in lung cancer.bioRxiv [Preprint]. 2024 Oct 28:2024.10.23.619897. doi: 10.1101/2024.10.23.619897. bioRxiv. 2024. Update in: Cancer Res. 2025 Jul 15;85(14):2574-2590. doi: 10.1158/0008-5472.CAN-24-3844. PMID: 39554171 Free PMC article. Updated. Preprint.
-
Emerging advances in defining the molecular and therapeutic landscape of small-cell lung cancer.Nat Rev Clin Oncol. 2024 Aug;21(8):610-627. doi: 10.1038/s41571-024-00914-x. Epub 2024 Jul 4. Nat Rev Clin Oncol. 2024. PMID: 38965396 Free PMC article. Review.
References
-
- Horn L, Mansfield AS, Szczęsna A, et al. : First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer. N Engl J Med 379:2220-2229, 2018 - PubMed
-
- Clinical Practice Guidelines in Oncology: Small Cell Lung Cancer. 2022. http://NCCN.org
-
- Paz-Ares L, Dvorkin M, Chen Y, et al. : Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): A randomised, controlled, open-label, phase 3 trial. Lancet 394:1929-1939, 2019 - PubMed
Publication types
MeSH terms
Substances
Associated data
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous